More side effects with CRT plus metformin in head, neck cancer

May 7, 2017

(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April 27 in Head & Neck.

Pei-Hung Chang, M.D., from the Chang Gung Memorial Hospital in Taoyuan City, Taiwan, and colleagues conducted a involving 252 patients with stages III, IVA, and IVB head and neck cancer undergoing concurrent CRT with and without treatment. The authors compared the clinical characteristics, treatment tolerance, toxicities, and survival for the 39 patients with and the 219 patients without metformin treatment.

The researchers found that the clinical characteristics were similar between the groups, and disease-free and overall survival were nearly identical. Compared to those not receiving metformin, receiving metformin were less likely to tolerate cisplatin, had more weight loss, were likely to receive lower doses of radiotherapy, needed more feeding tube support, and had grade ≥3 nausea/vomiting and hematological toxicities.

"Patients with head and undergoing concurrent CRT along with metformin treatment require more careful multidisciplinary assessment and supportive care to ensure successful completion of treatment and avoid treatment-related toxicities," the authors write.

Explore further: Metformin linked to lower risk of head, neck cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Metformin linked to lower risk of head, neck cancer

September 9, 2015
(HealthDay)—Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes, according to a study published in the September issue of Head & Neck.

Metformin use linked to less vitamin B12 measurement

February 17, 2017
(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published online Feb. 9 in the ...

Metformin use does not increase prostate cancer survival

April 11, 2017
(HealthDay)—Metformin use in combination with docetaxel chemotherapy does not significantly improve survival in patients with diabetes and metastatic castration-resistant prostate cancer, according to a study published ...

Prevalence of metformin use 0.7 percent in prediabetes

April 7, 2017
(HealthDay)—For U.S. adults with prediabetes, the prevalence of metformin use is 0.7 percent, according to a study published online April 3 in Diabetes Care.

Early glycemic control with metformin cuts CVD events

April 22, 2017
(HealthDay)—For patients with type 2 diabetes who initiate metformin, early achievement of low hemoglobin A1c (HbA1c) is associated with a reduction in the subsequent risk of cardiovascular events or death, according to ...

Diabetes drug takes aim at cancer's fuel source

January 25, 2017
In the last three years, researchers have shown that diabetic patients with head and neck cancer, may have better outcomes than non-diabetic patients when they are taking the drug metformin for their diabetes. In order to ...

Recommended for you

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.